Clomid for Women: Protocol, Success Rates, Twins and Side Effects

Clomid for women is the oldest oral fertility drug still in routine use, and the only use on its FDA label: treatment of ovulatory dysfunction in women who want to become pregnant. Clomiphene citrate blocks estrogen receptors in the hypothalamus, so the brain reads estrogen as low and releases more GnRH, then more FSH and LH from the pituitary. FSH recruits and grows a follicle; the LH surge that follows releases the egg. The drug does not add hormones. It removes the feedback that was keeping the woman's own system quiet, which is why it only works when the ovaries can still respond (how Clomid works covers the mechanism in detail).

The label lists who it is for: women with ovulatory dysfunction, not pregnant, without ovarian cysts other than those of polycystic ovary syndrome, with normal liver function, and whose partner's fertility and whose own tubes have been checked, because "impediments to achieving pregnancy must be excluded or adequately treated" before the first course.

The prescribing information is specific, and most clinics follow it closely:

The day-5 start is a convention, not a rule of biology; many clinics start on day 3, and the label's wording is "on or about the 5th day." What matters more is that the five tablets are taken on consecutive days at the same time, and that the woman is not pregnant when the course begins, which is why a pelvic examination is required before the first and each subsequent course.

Ovulation most often occurs 5 to 10 days after the last tablet, so on a day-5 start that is roughly cycle days 14 to 19. The label's instruction on timing is plain: intercourse "should be timed to coincide with the expected time of ovulation." Clinics add ovulation predictor kits, a mid-luteal progesterone blood test about seven days after expected ovulation, or ultrasound follicle tracking to confirm that a course worked. A basal body temperature chart is the label's own suggestion and still works, though it only confirms ovulation after the fact.

The three numbers get mixed up constantly, so here they are separately.

Ovulation. The 2003 American Society for Reproductive Medicine committee opinion puts it at about 8 in 10 women with ovulatory dysfunction. The label adds that "the majority of patients who are going to ovulate will do so after the first course," which is why a non-response at 50 mg is followed by a dose increase rather than more cycles at the same dose.

Pregnancy. In the trials behind the label, 7,578 women took clomiphene and "successful therapy characterized by pregnancy occurred in approximately 30%." The ASRM opinion gives the per-cycle view: among women who respond, roughly 15 pregnancies per 100 treatment cycles, rising to about 22 per 100 when there is no other fertility problem, which matches the rate in fertile couples. Over six to nine ovulatory cycles, about 70 to 75 of every 100 responders conceive.

Live birth. In the largest modern head-to-head trial, 750 women with PCOS were randomised to clomiphene or letrozole for up to five cycles (Legro et al., New England Journal of Medicine 2014). The live birth rate was 19.1% on clomiphene and 27.5% on letrozole, and ovulation was higher on letrozole at every visit. That trial is the reason letrozole has displaced Clomid as the first choice in PCOS at many clinics; the comparison is covered in Clomid vs letrozole. For women with other causes of anovulation, and in the many countries where letrozole is not licensed for fertility, Clomid remains the standard.

The label's outcome data cover 2,369 pregnancies: 7.98% were multiple, made up of 6.9% twins, 0.5% triplets, 0.3% quadruplets and 0.1% quintuplets. That is a higher rate than in unassisted pregnancies, but it still leaves more than 9 in 10 Clomid pregnancies as singletons. In the Legro trial the twin pregnancy rate was 7.4% on clomiphene versus 3.4% on letrozole.

The mechanism is simple: more FSH can mean more than one follicle matures. The dose does not reliably control it, and there is no protocol that raises the chance of twins without also raising the risks of a multiple pregnancy, which is why the label tells patients about the multiple-pregnancy rate before treatment.

From 8,029 women in the label's safety data, the events reported by more than 1%:

Two items carry their own warnings. Ovarian hyperstimulation syndrome is rare on Clomid compared with injectable gonadotropins, but the label notes it "may progress rapidly (within 24 hours to several days) and become a serious medical disorder," and advises the lowest effective dose. Severe pelvic pain, rapid weight gain or shortness of breath during or after a course needs same-day medical attention. Visual symptoms (blurring, spots, flashes) are "usually reversible" but can be prolonged or irreversible with higher doses and longer therapy, and the label's instruction is to stop the drug and have an eye examination if they appear.

A thinner uterine lining and reduced cervical mucus are the anti-estrogen effects clinicians discuss most, because they can lower the chance of implantation even in a cycle where ovulation worked; they are part of why pregnancy rates trail ovulation rates. The full list for both sexes is in Clomid side effects.

The drug needs a pituitary that can respond and ovaries with follicles to recruit. It works for:

It does not work for women with primary ovarian insufficiency, where FSH is already high and there are few follicles left, or for hypothalamic amenorrhea with very low estrogen, where there is no estrogen signal to block. The label's contraindications also rule out liver disease, abnormal uterine bleeding of unknown cause, ovarian cysts not caused by PCOS, uncontrolled thyroid or adrenal disease and pituitary tumours.

Women who ovulate on Clomid but do not conceive after three to four ovulatory cycles are usually moved on rather than continued, because the ASRM data show most conceptions in responders happen early and the label caps cyclic use at about six courses.

Ovulation itself has few reliable symptoms, which is why the label recommends a basal body temperature chart "or other appropriate tests." The signals that are actually informative:

Mild hot flashes during the five tablet days are the most common sign the drug is being absorbed, but they say nothing about whether a follicle is growing. Breast tenderness and bloating in the second half of the cycle are more consistent with ovulation having happened than anything felt during the course. Pregnancy symptoms cannot appear before implantation, which is about a week after ovulation, so anything felt in the first days after the tablets is the drug, not a pregnancy.

Clomid.org is an independent educational resource. We are not affiliated with any pharmaceutical manufacturer, compounding pharmacy, telehealth company or healthcare provider. This content is for informational purposes only and does not constitute medical advice. Images on this site are illustrative artwork made for editorial purposes; they do not show real products, packaging or labels and are not an advertisement or an offer to sell.